Elsevier

Pediatric Neurology

Volume 36, Issue 1, January 2007, Pages 17-24
Pediatric Neurology

Original article
Effect of Allopurinol Supplementation on Nitric Oxide Levels in Asphyxiated Newborns

https://doi.org/10.1016/j.pediatrneurol.2006.08.005Get rights and content

This study aimed to investigate the effect of allopurinol in the management of cerebral hypoxia-ischemia by monitoring nitric oxide levels of serum and cerebrospinal fluid. Sixty asphyxiated infants were divided randomly into two groups. Group I infants (n = 30) received allopurinol (40 mg/kg/day, 3 days) within 2 hours after birth. Group II infants (n = 30) received a placebo. Twenty healthy neonates served as control subjects. Cerebrospinal fluid and serum nitric oxide levels were measured within 0-24 hours and 72-96 hours after birth. Both serum and cerebrospinal fluid concentrations of nitric oxide were higher in severely asphyxiated infants (40.86 ± 8.97, 17.3 ± 3.63 μmol/L, respectively) but lower in mildly asphyxiated infants (25.85 ± 3.57, 5.70 ± 2.56 μmol/L, respectively) than in moderately asphyxiated infants (35.86 ± 5.38, 11.06 ± 3.37 μmol/L, respectively) within the first 0-24 hours after birth. Serum nitric oxide levels in control subjects were lower than those of moderately and severely asphyxiated infants. Serum nitric oxide levels of Group I infants within 72-96 hours after birth decreased significantly from their corresponding levels within 0-24 hours after birth. The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.

Introduction

Hypoxic-ischemic encephalopathy of the newborn has been studied extensively in various animal models and in humans to investigate the pathogenesis and treatment options. Treatment protocols of hypoxic-ischemic encephalopathy in newborn infants range from no therapy at all to extensive use of a variety of medications. New management strategies include the use of inhibitors of xanthine oxidase, excitatory amino acid antagonist, calcium channel blockers, and antioxidant enzymes [1], [2]. Most of the animal research has pointed to the role of excitatory amino acids, cytokines, and nitric oxide (NO) determining the extent of the pathology [3], [4], [5]. Ergenekon et al. reported that cerebrospinal fluid NO levels elevated with increasing severity of hypoxic-ischemic encephalopathy during the first 24-72 hours of the hypoxic insult in asphyxiated newborns [6]. Recently the production of NO, a free radical, has been demonstrated to be increasing during cerebral hypoxia-ischemia [7]. NO is formed directly from the guanidino nitrogen of l-arginine by NO synthase. Nitric oxide synthase is an unusual oxidative enzyme in that most other enzymes consume one or two electrons for similar functions. Once it was recognized that NO synthase is a calmodulin-dependent enzyme, NO synthase could be purified to homogeneity from cerebellum [8]. Soon thereafter, purified NO synthase could be isolated from a variety of other brain tissues in a variety of species [9]. It was demonstrated that there were varying effects of cerebral NO in asphyxiated knockout mice for different isoforms of NO synthase [3]. Neuronal NO synthase is activated shortly after the asphyxial event and is known to cause an increase in the neuronal NO which produces several neurotoxic effects. After the first 12-24 hours of asphyxia, inducible NO synthase in the glial cells becomes activated, causing large increases in cerebral NO, which is now considered to have a major role in the ongoing neurotoxicity following asphyxia [3]. Despite a great deal of evidence about the double-edged effects and the role of NO in animals in hypoxic-ischemic encephalopathy, few studies have been conducted in asphyxiated human newborns with regard to cerebral NO production [6], [10].

Xanthine oxidase–derived superoxide exerts its actions in the overall context of various endogenous oxidant and antioxidant systems. For example, NO can act as an endogenous suppressor of xanthine oxidase activity [11]. Because in many pathophysiologic conditions there is an impairment of endogenous NO production, a reduced level of the tonic, NO-mediated suppression of xanthine oxidase may actually lead to increased superoxide generation and pathophysiologic positive feed-forward cycles. At the same time, there may also be a xanthine oxidase–derived superoxide-dependent tonic suppression of NO synthase activity, which may lead to an enhancement of NO production in response to xanthine oxidase inhibition in vivo [12]. There is some evidence that xanthine oxidase can catalyze the reduction of nitrite and nitrate (normally the decomposition products of NO) back to NO [13]. These activities are more prominent under acidic conditions and may contribute to a pathophysiologic enhancement of NO generation in ischemic or hypoxic tissues. Xanthine oxidase–derived superoxide can rapidly react with NO or nitrosothiols in its vicinity to form the cytotoxic oxidant species peroxynitrite, which can lead to a variety of oxidative and nitrosative injury to proteins, lipids, and deoxyribonucleic acid in the vicinity of xanthine oxidase [14]. It is conceivable that after binding of circulating xanthine oxidase to the endothelium, xanthine oxidase–derived superoxide can combine with endothelially derived NO (produced by the endothelial NO synthase), and the subsequent formation of peroxynitrite and the activation of downstream pathways of cell injury can lead to endothelial and tissue injury in various pathophysiologic conditions [15], [16]. Therefore administration of xanthine oxidase–inhibiting compounds such as allopurinol might have the potential to decrease cerebral injury of the asphyxiated newborns. The aim of the present study was to investigate the effect of allopurinol on cerebrospinal fluid and serum NO concentrations in cerebral injury following birth asphyxia as well as to observe if there is a therapeutic window after the hypoxic insult with regard to NO production.

Section snippets

Patients and Methods

From January 1, 2003, to February 1, 2005, a total of 3658 neonates were admitted to the neonatal intensive care unit of Gevher Nesibe Hospital. Patients with gestation of 37 weeks or more and with history of perinatal asphyxia documented by three or more of the following were considered eligible for the study: abnormal level of consciousness; abnormal muscle tone; abnormal reflexes; seizures within the first 72 hours of life; and three or more of the following: low Apgar scores (5-minute Apgar

Results

The clinical characteristics of infants are summarized in Table 1. The asphyxiated and control infants had statistically similar birth weights, sex, delivery mode, and gestation (P > 0.05). The clinical characteristics of Groups I and II are detailed in Table 2. The groups were also similar according to birth weight, sex, delivery mode, Apgar score at 5 minutes, arterial blood base deficit, and gestation (P > 0.05). Cerebrospinal fluid and blood cultures drawn at the time of sampling revealed

Discussion

In this study, serum NO levels in the moderately and severely asphyxiated newborns were significantly higher than in control subjects, and cerebrospinal fluid levels of NO were correlated with the degree of hypoxic-ischemic encephalopathy, supporting the role of NO in the pathophysiology following asphyxia. In order to assess the role of NO in ischemic damage, it is necessary to know where and when NO is produced in the brain during and after ischemia. It appears that the production of NO

References (38)

  • Y. Shi et al.

    Plasma nitric oxide levels in newborn infants with sepsis

    J Pediatr

    (1993)
  • R.C. Vannucci

    Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy

    Pediatrics

    (1995)
  • A.J. Du Plessis et al.

    Hypoxic-ischemic brain injury in the newborn: Cellular mechanisms and potential strategies for neuroprotection

    Clin Perinatol

    (1997)
  • A.M. Moskowitz et al.

    Nitric oxide and cerebral ischemia

  • E. Ergenekon et al.

    Cerebrospinal fluid and serum nitric oxide levels in asphyxiated newborns

    Biol Neonate

    (1999)
  • A. Buisson et al.

    The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia

    Br J Pharmacol

    (1992)
  • D.S. Bredt et al.

    Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme

    Proc Natl Acad Sci U S A

    (1990)
  • A. Mechurova et al.

    The hypoxanthine level in cord blood—a potential indicator of foetal hypoxia

    Physiol Bohemoslov

    (1985)
  • K. Gucuyener et al.

    Cerebrospinal fluid levels of nitric oxide and nitrotyrosine in neonates with mild hypoxic-ischemic encephalopathy

    J Child Neurol

    (2002)
  • Cited by (64)

    • Distribution of neuronal nitric oxide synthase immunoreactivity in adult male Sprague-Dawley rat brain

      2019, Acta Histochemica
      Citation Excerpt :

      Studies have shown that NO modulating bidirectional synaptic plasticity (LTP or LTD) goes through the postsynaptic Ca2+ levels and glutamate-nitric oxide-cGMP pathway in Purkinje cells within the cerebellum, thereby, contributing to cerebellar learning associated with motor control and coordination (Cabrera-Pastor et al., 2016; Contestabile, 2012). On the other hand, human studies have shown that activated nNOS with increased NO transmission in the cerebellum is associated with asphyxia at birth, suggesting that post-asphyxic excitotoxicity is induced by excessive NO release (Gunes et al., 2007; Perlman, 2006). High nNOS activity was also seen throughout the cerebellum in the rat model of perinatal asphyxia, and this study suggested that the inhibition of NO production in specific regions of the preterm brain play a crucial role in development of motor control and coordination. (

    • Novel interventions to reduce oxidative-stress related brain injury in neonatal asphyxia

      2019, Free Radical Biology and Medicine
      Citation Excerpt :

      However, antenatal administration of allopurinol during fetal hypoxia did not reduce the neuronal damage marker S100β in umbilical cord blood [57]. Three small trials including a total of 114 infants [58–60] examined postnatal administration of allopurinol to infants with HIE. Long-term outcome data of two of these studies suggest a reduction in the combined outcome of death or severe neurodevelopmental impairment from 65% in the control group to 25% in the allopurinol group in moderately asphyxiated infants.

    • Pharmacologic Prevention and Treatment of Neonatal Brain Injury

      2019, Clinics in Perinatology
      Citation Excerpt :

      Given the proposed mechanism of action, these authors postulated that administration within 4 hours after birth might have been outside of the therapeutic window and that earlier or antenatal administration should be investigated. In support of this idea, another small randomized control trial tested 40 mg/kg of allopurinol within 2 hours of birth for term neonates with mild, moderate, or severe encephalopathy (this dose was repeated daily for 3 days).34 Three groups were compared including 30 neonates who received allopurinol (treatment group), 30 neonates who received placebo, and a control group of 20 healthy term neonates.

    • Hypoxic-Ischemic Injury in the Term Infant

      2018, Volpe's Neurology of the Newborn
    View all citing articles on Scopus
    View full text